OncoCyte Corp expected to post a loss of 13  cents a share - Earnings Preview

Insight Molecular Diagnostics

08/03/2022 21:32

* OncoCyte Corp  OCX.OQ   OCX.O  is expected to show a rise
in
quarterly revenue when it reports  results on March 10. 
    * The Irvine California-based  company is expected to report
 a
621.9% increase in revenue to $3.631 million from $503 thousand
a year ago, according to the mean estimate from 6 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for OncoCyte Corp is
for a
loss of 13 cents per share. For the same quarter last year, the
company reported a loss of 9 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for OncoCyte
Corp is
$5​, above​ its last closing price of $1.26. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.12       -0.12      -0.15     Missed  -29.3
 Jun. 30 2021  -0.09       -0.10      -0.12     Missed  -20
 Mar. 31 2021  -0.11       -0.10      -0.05     Beat    50​
 Dec. 31 2020  -0.12       -0.11      -0.09     Beat    18.2
 ​​Sep.        -0.10       -0.09      -0.10     Missed  -5.3
 30 2020                                                
 Jun. 30 2020  -0.11       -0.10      -0.14     Missed  -34.6​
 Mar. 31 2020  -0.11       -0.11      -0.13     Missed  -22.6
 Dec. 31 2019  -0.07       -0.09      -0.14     Missed  -52.2
 This summary was machine generated March 8 at 21:31 GMT.  All
figures in US dollars  unless otherwise stated